SAN FRANCISCO--(BUSINESS WIRE)-- Fitbit (NYSE: FIT) today launched the Fitbit Heart Study, its first large-scale, virtual study to validate the use of its wearable technology to identify episodes of irregular heart rhythm suggestive of atrial fibrillation (AFib), the most common form of heart rhythm irregularity. This study is part of the Company’s broader strategy to make easy-to-use tools that accelerate detection of a range of conditions more accessible. The Fitbit Heart Study aims to enroll hundreds of thousands of people, and its results will support the Company’s regulatory submissions globally.
External News Article:
Add reference to external site news article